Latest Albany Molecular Research (AMRI) Headlines
Post# of 18
Posted On: 03/13/2014 5:09:31 AM
Latest Albany Molecular Research (AMRI) Headlines
Shares of AMRI Up 35.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 06, 9:43AM CST
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on February 12th, 2014 at $11.62. In approximately 3 weeks, Albany Molecular Research has returned 35.54% as of today's recent price of $15.75.
Stock Movements, Upcoming Conferences, Financial Results, and Public Offering Closings - Analyst Notes on Community Health Systems, United Therapeutics, Thoratec, AMRI, and Cytokinetics
PR Newswire - Wed Mar 05, 6:15AM CST
Editor Note: For more information about this release, please scroll to bottom.
The US Clinical Research Market Outlook to 2017: Value Chain, Market Size and Segmentation by Major Therapeutic Areas
M2 - Mon Mar 03, 11:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/vt6rd9/the_us_clinical) has announced the addition of the "The US Clinical Research Market Outlook to 2017 - Led by Aging Population and Rise of Chronic Diseases" report to their offering. The report titled The US Clinical Research Market Outlook to 2017 - Led by Aging Population and Rise of Chronic Diseases' provides a comprehensive analysis of the various aspects such as market size, segmentation, trends and developments and future projections of the therapeutic areas of Oncology, Central Nervous System Disorders, Cardiovascular Diseases, Infectious Diseases and Metabolic disorders as key segments of the market. The report also provides a detailed explanation of the various macro and industry factors which are driving the growth of clinical research in the US. - The market size of The US Clinical Research Market on the basis of revenue earned by the contract research organizations in the country. - The market segmentation of The US Clinical Research Market on the basis of therapeutic areas of Oncology, Central Nervous System Disorders, Cardiovascular Diseases, Infectious Diseases and Metabolic Disorders. - The market segmentation of Oncology on the basis revenue generated in key medical conditions of Oncology which include Breast Cancer, Lung Cancer, Leukemia, Prostate Cancer, Non Small Cell Lung Cancer and other kinds of cancers. - The market size of Breast Cancer, Lung Cancer, Leukemia, Prostate Cancer, Non Small Cell Lung Cancer and other kinds of cancers on the basis of revenue generated from clinical research in these areas. - Future Outlook and Projections of Oncology and its key medical conditions. - The market size of Central Nervous System Disorders on the basis of revenue. - The market segmentation of Central Nervous System Disorders on the basis revenue generated in its key medical conditions which comprise of Strokes, Schizophrenia, Alzheimer, Multiple Sclerosis, Epilepsy and other Central Nervous System Disorders. - Future Outlook and Projections of Central Nervous System Disorders and its key medical conditions. - The market size of Cardiovascular Diseases on the basis of revenue. - The market segmentation of Cardiovascular Diseases on the basis revenue generated in its key medical conditions which comprise of Coronary Artery Disease and Heart Failures. - Future Outlook and Projections of Cardiovascular Diseases and its key medical conditions. - The market size of Infectious Diseases on the basis of revenue. - The market segmentation of Infectious Diseases on the basis revenue generated in its key medical conditions which comprise of HIV/AIDS and Hepatitis (A, B and C) - Future Outlook and Projections of Infectious Diseases and its key medical conditions. - The market size of metabolic disorders on the basis of revenue. - The market segmentation of Metabolic Disorders on the basis revenue generated in its key medical conditions which comprise of Diabetes and other metabolic disorders. - Future Outlook and Projections of Metabolic Disorders and its key medical conditions. - The market size of other therapeutic areas. - Future Outlook and Projections of other therapeutic areas. - The Future Outlook and Projections of The US Clinical Research Market on the basis of revenue. Companies Mentioned: - Albany Molecular Research inc - Charles River - Covance inc - ICON - INC Research - Inventiv Health Care - PRA International - Parexel - Pharmaceutical Product Development (PPD) - Quintiles inc For more information visit http://www.researchandmarkets.com/research/vt...s_clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Albany Molecular Research Shares Up 35.6% Since SmarTrend's Buy Recommendation (AMRI)
Comtex SmarTrend(R) - Thu Feb 27, 9:13AM CST
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on February 12th, 2014 at $11.62. In approximately 2 weeks, Albany Molecular Research has returned 35.63% as of today's recent price of $15.76.
Albany Molecular Research Inc. (AMRI) Selects FirstLight Fiber for 10 Gbps Network Upgrade
Marketwire - Thu Feb 27, 7:05AM CST
FirstLight Fiber, a facilities-based telecommunications service provider operating fiber optic networks in Upstate New York and Northern New England with connectivity to Canada, announced today that Albany Molecular Research Inc. (NASDAQ: AMRI) has chosen FirstLight to upgrade its network.
AMRI CEO to Present at Barclays Global Healthcare Conference
PR Newswire Europe - Thu Feb 27, 7:02AM CST
Albany Molecular Research Inc. announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at Barclays Global Healthcare Conference on Wednesday, March 12, 2014 at 2:00 p.m. ET.
PATTISON Outdoor Advertising is Proud to Present the Unique Art in Transit Programme
Marketwire Canada - Thu Feb 13, 4:59AM CST
Editors note: There is a photo associated with this press release.
Aurigene and Pierre Fabre Pharmaceuticals Announce a Licensing Agreement for a New Cancer Therapeutic in Immuno-oncology: AUNP12, an Immune Checkpoint Modulator Targeting the PD-1 Pathway
PR Newswire - Thu Feb 13, 2:14AM CST
Pierre Fabre, the third largest French pharmaceutical company, and Aurigene, a leading biotech company based in India, today announced that the two companies have entered into a collaborative license, development and commercialization agreement granting Pierre Fabre global Worldwide rights (excluding India) to a new immune checkpoint modulator, AUNP-12.
AMRI Announces Fourth Quarter and Full Year 2013 Results and Provides 2014 Guidance
PR Newswire Europe - Wed Feb 12, 7:01AM CST
-- Full Year 2013 Contract Revenue Growth of 11% to $210 Million and Adjusted Diluted EPS of $0.70
Lorillard, Inc. Reports Fourth Quarter And Full Year 2013 Results
PR Newswire - Wed Feb 12, 6:00AM CST
Lorillard, Inc. (NYSE: LO) announced today its results for the quarter and year ended December 31, 2013.
Saban's Power Rangers Megaforce, Power Rangers Super Megaforce And Digimon Fusion Coming To Cartoon Network Latin America
PR Newswire - Tue Feb 11, 7:00AM CST
Saban Brands and Cartoon Network announced today that Power Rangers Megaforce, Power Rangers Super Megaforce and Digimon Fusion have been licensed to Cartoon Network Latin America for broadcast beginning in 2014. Additionally, Cartoon Network Latin America will serve as licensing and merchandising agents for both the Power Rangers franchise and Digimon Fusion. MarVista Entertainment, the series' exclusive international distributor, negotiated the agreement in partnership with Saban Brands.
Form 4: Update Filing for Albany Molecular Research Inc (AMRI)
Vickers Stock Research - Fri Feb 07, 4:27AM CST
EUROCASTLE INVESTMENT LIMITED
AMRI to Announce Fourth Quarter and Full Year Results
PR Newswire Europe - Wed Jan 29, 7:01AM CST
AMRI today announced it will issue fourth quarter and full year financial results before the opening of the market on Wednesday, February 12, 2014. Following the release of its results, the company will host a conference call and simultaneous audio webcast at 10 a.m. ET.
Commit To Purchase Albany Molecular Research At $7.50, Earn 9.6% Annualized Using Options
StockOptionsChannel.com - Thu Jan 23, 10:36AM CST
Investors considering a purchase of Albany Molecular Research, Inc. shares, but cautious about paying the going market price of $11.07/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Canfor Corporation and Canfor Pulp Products Inc. Announce Fourth Quarter Results Conference Call
Marketwire - Wed Jan 15, 5:19PM CST
Canfor Corporation (TSX: CFP) and Canfor Pulp Products Inc. (TSX: CFX) will hold a joint conference call on Thursday, February 6, 2014 at 8:00 AM PST to discuss their respective fourth quarter 2013 financial and operating results. To participate in the call, please dial one of the following numbers:
Rick's Cabaret International, Inc. to Present at Noble Financial Conference on January 20, 2014
PR Newswire - Wed Jan 15, 8:00AM CST
Rick's Cabaret International, Inc. (NasdaqGM: RICK) today announced that President and CEO Eric Langan will present at Noble Financial Capital Markets' Tenth Annual Equity Conference in Sandpiper Bay, Florida, on Monday, January 20, 2014 at 4:00 PM ET.
Shares of AMRI Up 35.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 06, 9:43AM CST
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on February 12th, 2014 at $11.62. In approximately 3 weeks, Albany Molecular Research has returned 35.54% as of today's recent price of $15.75.
Stock Movements, Upcoming Conferences, Financial Results, and Public Offering Closings - Analyst Notes on Community Health Systems, United Therapeutics, Thoratec, AMRI, and Cytokinetics
PR Newswire - Wed Mar 05, 6:15AM CST
Editor Note: For more information about this release, please scroll to bottom.
The US Clinical Research Market Outlook to 2017: Value Chain, Market Size and Segmentation by Major Therapeutic Areas
M2 - Mon Mar 03, 11:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/vt6rd9/the_us_clinical) has announced the addition of the "The US Clinical Research Market Outlook to 2017 - Led by Aging Population and Rise of Chronic Diseases" report to their offering. The report titled The US Clinical Research Market Outlook to 2017 - Led by Aging Population and Rise of Chronic Diseases' provides a comprehensive analysis of the various aspects such as market size, segmentation, trends and developments and future projections of the therapeutic areas of Oncology, Central Nervous System Disorders, Cardiovascular Diseases, Infectious Diseases and Metabolic disorders as key segments of the market. The report also provides a detailed explanation of the various macro and industry factors which are driving the growth of clinical research in the US. - The market size of The US Clinical Research Market on the basis of revenue earned by the contract research organizations in the country. - The market segmentation of The US Clinical Research Market on the basis of therapeutic areas of Oncology, Central Nervous System Disorders, Cardiovascular Diseases, Infectious Diseases and Metabolic Disorders. - The market segmentation of Oncology on the basis revenue generated in key medical conditions of Oncology which include Breast Cancer, Lung Cancer, Leukemia, Prostate Cancer, Non Small Cell Lung Cancer and other kinds of cancers. - The market size of Breast Cancer, Lung Cancer, Leukemia, Prostate Cancer, Non Small Cell Lung Cancer and other kinds of cancers on the basis of revenue generated from clinical research in these areas. - Future Outlook and Projections of Oncology and its key medical conditions. - The market size of Central Nervous System Disorders on the basis of revenue. - The market segmentation of Central Nervous System Disorders on the basis revenue generated in its key medical conditions which comprise of Strokes, Schizophrenia, Alzheimer, Multiple Sclerosis, Epilepsy and other Central Nervous System Disorders. - Future Outlook and Projections of Central Nervous System Disorders and its key medical conditions. - The market size of Cardiovascular Diseases on the basis of revenue. - The market segmentation of Cardiovascular Diseases on the basis revenue generated in its key medical conditions which comprise of Coronary Artery Disease and Heart Failures. - Future Outlook and Projections of Cardiovascular Diseases and its key medical conditions. - The market size of Infectious Diseases on the basis of revenue. - The market segmentation of Infectious Diseases on the basis revenue generated in its key medical conditions which comprise of HIV/AIDS and Hepatitis (A, B and C) - Future Outlook and Projections of Infectious Diseases and its key medical conditions. - The market size of metabolic disorders on the basis of revenue. - The market segmentation of Metabolic Disorders on the basis revenue generated in its key medical conditions which comprise of Diabetes and other metabolic disorders. - Future Outlook and Projections of Metabolic Disorders and its key medical conditions. - The market size of other therapeutic areas. - Future Outlook and Projections of other therapeutic areas. - The Future Outlook and Projections of The US Clinical Research Market on the basis of revenue. Companies Mentioned: - Albany Molecular Research inc - Charles River - Covance inc - ICON - INC Research - Inventiv Health Care - PRA International - Parexel - Pharmaceutical Product Development (PPD) - Quintiles inc For more information visit http://www.researchandmarkets.com/research/vt...s_clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Albany Molecular Research Shares Up 35.6% Since SmarTrend's Buy Recommendation (AMRI)
Comtex SmarTrend(R) - Thu Feb 27, 9:13AM CST
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on February 12th, 2014 at $11.62. In approximately 2 weeks, Albany Molecular Research has returned 35.63% as of today's recent price of $15.76.
Albany Molecular Research Inc. (AMRI) Selects FirstLight Fiber for 10 Gbps Network Upgrade
Marketwire - Thu Feb 27, 7:05AM CST
FirstLight Fiber, a facilities-based telecommunications service provider operating fiber optic networks in Upstate New York and Northern New England with connectivity to Canada, announced today that Albany Molecular Research Inc. (NASDAQ: AMRI) has chosen FirstLight to upgrade its network.
AMRI CEO to Present at Barclays Global Healthcare Conference
PR Newswire Europe - Thu Feb 27, 7:02AM CST
Albany Molecular Research Inc. announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at Barclays Global Healthcare Conference on Wednesday, March 12, 2014 at 2:00 p.m. ET.
PATTISON Outdoor Advertising is Proud to Present the Unique Art in Transit Programme
Marketwire Canada - Thu Feb 13, 4:59AM CST
Editors note: There is a photo associated with this press release.
Aurigene and Pierre Fabre Pharmaceuticals Announce a Licensing Agreement for a New Cancer Therapeutic in Immuno-oncology: AUNP12, an Immune Checkpoint Modulator Targeting the PD-1 Pathway
PR Newswire - Thu Feb 13, 2:14AM CST
Pierre Fabre, the third largest French pharmaceutical company, and Aurigene, a leading biotech company based in India, today announced that the two companies have entered into a collaborative license, development and commercialization agreement granting Pierre Fabre global Worldwide rights (excluding India) to a new immune checkpoint modulator, AUNP-12.
AMRI Announces Fourth Quarter and Full Year 2013 Results and Provides 2014 Guidance
PR Newswire Europe - Wed Feb 12, 7:01AM CST
-- Full Year 2013 Contract Revenue Growth of 11% to $210 Million and Adjusted Diluted EPS of $0.70
Lorillard, Inc. Reports Fourth Quarter And Full Year 2013 Results
PR Newswire - Wed Feb 12, 6:00AM CST
Lorillard, Inc. (NYSE: LO) announced today its results for the quarter and year ended December 31, 2013.
Saban's Power Rangers Megaforce, Power Rangers Super Megaforce And Digimon Fusion Coming To Cartoon Network Latin America
PR Newswire - Tue Feb 11, 7:00AM CST
Saban Brands and Cartoon Network announced today that Power Rangers Megaforce, Power Rangers Super Megaforce and Digimon Fusion have been licensed to Cartoon Network Latin America for broadcast beginning in 2014. Additionally, Cartoon Network Latin America will serve as licensing and merchandising agents for both the Power Rangers franchise and Digimon Fusion. MarVista Entertainment, the series' exclusive international distributor, negotiated the agreement in partnership with Saban Brands.
Form 4: Update Filing for Albany Molecular Research Inc (AMRI)
Vickers Stock Research - Fri Feb 07, 4:27AM CST
EUROCASTLE INVESTMENT LIMITED
AMRI to Announce Fourth Quarter and Full Year Results
PR Newswire Europe - Wed Jan 29, 7:01AM CST
AMRI today announced it will issue fourth quarter and full year financial results before the opening of the market on Wednesday, February 12, 2014. Following the release of its results, the company will host a conference call and simultaneous audio webcast at 10 a.m. ET.
Commit To Purchase Albany Molecular Research At $7.50, Earn 9.6% Annualized Using Options
StockOptionsChannel.com - Thu Jan 23, 10:36AM CST
Investors considering a purchase of Albany Molecular Research, Inc. shares, but cautious about paying the going market price of $11.07/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Canfor Corporation and Canfor Pulp Products Inc. Announce Fourth Quarter Results Conference Call
Marketwire - Wed Jan 15, 5:19PM CST
Canfor Corporation (TSX: CFP) and Canfor Pulp Products Inc. (TSX: CFX) will hold a joint conference call on Thursday, February 6, 2014 at 8:00 AM PST to discuss their respective fourth quarter 2013 financial and operating results. To participate in the call, please dial one of the following numbers:
Rick's Cabaret International, Inc. to Present at Noble Financial Conference on January 20, 2014
PR Newswire - Wed Jan 15, 8:00AM CST
Rick's Cabaret International, Inc. (NasdaqGM: RICK) today announced that President and CEO Eric Langan will present at Noble Financial Capital Markets' Tenth Annual Equity Conference in Sandpiper Bay, Florida, on Monday, January 20, 2014 at 4:00 PM ET.
(0)
(0)Albany Molecular Research (AMRI) Stock Research Links
Scroll down for more posts ▼